Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data AGIOS PHARMACEUTICALS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
69.9
43
94.4
118
0
0
14.2
26.8
36.5
54
Cost of revenue
0
0
1.4
1.32
0
0
1.7
2.88
4.17
6.35
Gross profit
69.9
43
93
117
0
0
12.5
23.9
32.3
47.7
Research and development
220
293
341
214
221
257
280
296
301
340
Selling, general and administrative
50.7
71.1
114
102
115
121
122
120
157
180
General and administrative
50.7
71.1
Operating expenses
271
364
457
Operating income
-201
-321
-362
-316
-336
-378
-389
-391
-426
-472
Interest income
2.51
6.12
16.5
14.9
6.61
0.84
12.8
Other non-operating income
0
0
14.4
6.75
6.06
6.49
1.96
Pre-tax income
-198
-315
-346
-301
-329
-357
-232
-352
718
-414
Income tax
0
0
0
0
0
0
44.2
-1.02
Income from continuing operations
-301
-329
-357
-232
-352
Net income
-198
-315
-346
-411
-327
1,605
-232
-352
674
-413
EBITDA
-195
-314
-355
-308
-327
-370
-381
-385
-420
-467
EPS, basic
-5.07
-6.75
-6.03
-6.86
-4.74
26.55
-4.23
-6.33
11.86
-7.12
EPS, diluted
-5.07
-6.75
-6.03
-6.86
-4.74
26.55
-4.23
-6.33
11.64
-7.12
Shares, basic (weighted)
39.1
46.6
57.4
60
69
60.4
54.8
55.7
56.8
58
Shares, diluted (weighted)
39.1
46.6
57.4
60
69
60.4
54.8
55.7
57.9
58
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
161
103
70.5
80.9
127
203
139
88.2
76.2
89.1
Short-term investments
381
515
484
445
817
644
689
817
765
Inventory
0
0.87
7.33
14.7
0
8.49
19.1
27.6
32.9
Other current assets
10.3
17.7
17.2
24.2
15.9
39.8
39
35
40.2
44.1
Total current assets
560
445
614
612
637
1,064
833
834
966
942
Property, plant and equipment
25.3
24.4
24.3
31.5
30.8
28.9
23
15.4
11.7
10.8
Lease right-of-use assets
93.6
84.7
75.1
65.1
54.4
42.9
30.5
Long-term investments
220
153
97.6
266
314
29.4
638
310
Other non-current assets
1.62
0.89
0.24
0
0
2.9
3.96
4.06
4.72
3.93
Total assets
619
614
858
891
853
1,438
1,239
937
1,663
1,297
Accounts payable
17.1
22.8
17.9
21.9
17.7
16.7
18.6
9.78
16.6
18.4
Accrued liabilities
32
34
42.1
53.1
30.8
32
30.4
43.2
46.9
45.5
Deferred revenue
35.9
37.8
32.7
10.9
0
0
Total current liabilities
88.4
94.9
93.5
92.9
94.4
59.8
62.6
68
81.2
82.2
Lease liabilities
106
97.5
85.7
72
57
40.2
21.8
Other non-current liabilities
0
3.28
1.16
0.88
0.09
Total liabilities
261
239
171
250
453
146
138
126
122
104
Paid-in capital
842
1,175
1,794
2,156
2,243
2,334
2,386
2,437
2,494
2,555
Retained earnings
-483
-798
-1,105
-1,516
-1,843
-239
-471
-823
-149
-562
Treasury stock
0
-802
-802
-802
-802
-802
Shareholders' equity
359
376
688
641
400
1,292
1,101
811
1,541
1,193
Total equity
359
376
688
641
400
1,292
1,101
811
1,541
1,193
Total liabilities and equity
619
614
858
891
853
1,438
1,239
937
1,663
1,297
Shares outstanding
42.2
48.8
58.2
68.4
69.3
54.3
55
55.9
57.2
58.4
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-198
-315
-346
-411
-327
1,605
-232
-352
674
-413
Depreciation and amortization
5.71
6.43
7.17
8.09
9.4
8.8
8.4
6.6
5.7
5.2
Stock-based compensation
42.1
47.8
73.4
58.1
61.6
53.5
49.3
44.8
42.8
52.6
Deferred income tax
0
Change in receivables
0
0
-2.21
-0.6
-1.3
-6.47
Change in inventory
0
0
-0.87
-6.46
0
0
-8.49
-10.6
-8.54
-5.3
Change in payables
3.5
5.33
-5.49
4.16
3.33
1.86
3.44
-8.73
6.6
1.75
Cash from operations
38.6
-285
-304
-371
-291
-407
-309
-296
-390
-373
Capital expenditures
-9.92
-4.63
-6.99
-12
-14.1
-5.74
-4.88
-1
-1.69
-4.32
Purchases of investments
-689
-933
-489
-557
-1,378
-1,031
-418
-1,542
-642
Cash from investing
-119
-57.9
-274
91.4
75.7
1,249
243
240
363
377
Stock issued
162
270
516
277
0
0
Share buybacks
0
0
-802
0
0
Cash from financing
170
285
546
290
262
-766
2.35
5.43
14.4
8.68
Net change in cash
89
-58
-32.2
10.4
46.5
75.7
-63.9
-51.1
-12
12.9
Free cash flow
28.6
-290
-311
-383
-305
-413
-314
-297
-392
-377
Income taxes paid
0
0
16.1
0
1.57
43.2
0.63
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $32.58 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
92.0%
Gross profit / revenue.
Operating margin
-466.8%
Operating income / revenue.
Net margin
-418.2%
Net income / revenue.
FCF margin
-371.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-366.7%
Cash from operations / revenue.
Return on equity (ROE)
-40.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-37.1%
Net income / average total assets.
Return on invested capital (ROIC)
-39.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
362.8%
Research and development expense / revenue.
SG&A / revenue
196.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
59.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
4.7%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
48.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
56.0%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
47.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
56.1%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income growth, 1y
-161.3%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-161.2%
EPS vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-22.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
2.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
24.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-22.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
1.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
8.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-3.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.2x
Current assets / current liabilities.
Quick ratio
8.80x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.80x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.65
Revenue / diluted weighted shares.
FCF per share
-$6.14
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$6.06
Cash from operations / diluted weighted shares.
Book value per share
$17.21
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
19.8x
Market cap / revenue.
P/B
1.90x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.90x
Market cap / tangible book value, when positive.
EV/Sales
13.5x
Enterprise value / revenue.
FCF yield
-18.8%
Free cash flow / market cap.
Earnings yield
-21.1%
Net income / market cap (the inverse of P/E).
What was AGIOS PHARMACEUTICALS, INC.'s revenue in fiscal 2025?
AGIOS PHARMACEUTICALS, INC. reported revenue of $54.0M for fiscal 2025, 48% higher than the year before.
Was AGIOS PHARMACEUTICALS, INC. profitable in fiscal 2025?
No. It reported a net loss of $412.8M.
How much free cash flow did AGIOS PHARMACEUTICALS, INC. generate in fiscal 2025?
Cash from operations of $373.0M minus capital expenditures of $4.3M left free cash flow of -$377.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.